Multi-modality strategy for creating innovative drugs

In recent years, a wide variety of modalities, including small molecules, antibodies, nucleic acids, and gene therapies, have been successfully applied to drug discovery and have demonstrated significant achievements. The diversification and advancement in modalities have expanded the range of targets and diseases we can address, opening new opportunities for drug discovery. At Daiichi Sankyo, we are advancing a multi-modality strategy that shifts the focus from solely small molecules to broader range of modalities. In this strategy, it is critical to select the appropriate modality for each target to transform research concepts into viable drug candidates. Additionally, developing competitive modality technologies and platforms is essential for continuously creating innovative drugs with improved treatment outcomes. Our multi-modality strategy enables us to combine different modality technologies into more advanced modality development.